131 related articles for article (PubMed ID: 10478643)
21. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
Atkins MB; Dutcher J; Weiss G; Margolin K; Clark J; Sosman J; Logan T; Aronson F; Mier J;
Med Oncol; 2001; 18(3):197-207. PubMed ID: 11917944
[TBL] [Abstract][Full Text] [Related]
22. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function.
Tartour E; Latour S; Mathiot C; Thiounn N; Mosseri V; Joyeux I; D'Enghien CD; Lee R; Debre B; Fridman WH
Int J Cancer; 1995 Oct; 63(2):205-12. PubMed ID: 7591205
[TBL] [Abstract][Full Text] [Related]
23. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
24. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
Fortis C; Ferrero E; Besana C; Biffi M; Heltai S; Galli L; Borri A; Schoenheit A; Rugarli C
Cancer Immunol Immunother; 1990; 32(3):161-6. PubMed ID: 2289209
[TBL] [Abstract][Full Text] [Related]
25. Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.
Cheriyan VT; Thomas C; Balaram P
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1435-44. PubMed ID: 21809032
[TBL] [Abstract][Full Text] [Related]
26. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
27. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules.
Kurt RA; Urba WJ; Smith JW; Schoof DD
Int J Cancer; 1998 Sep; 78(1):16-20. PubMed ID: 9724088
[TBL] [Abstract][Full Text] [Related]
28. Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/zeta complex.
Thome M; Duplay P; Guttinger M; Acuto O
J Exp Med; 1995 Jun; 181(6):1997-2006. PubMed ID: 7539035
[TBL] [Abstract][Full Text] [Related]
29. T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck.
Horak ID; Gress RE; Lucas PJ; Horak EM; Waldmann TA; Bolen JB
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1996-2000. PubMed ID: 2000405
[TBL] [Abstract][Full Text] [Related]
30. Signal transduction of interleukin 2 in human natural killer cells: involvement of the p56lck tyrosine kinase.
Vitte-Mony I; Delespine-Carmagnat M; Bertoglio JH
Mol Immunol; 1994 Jun; 31(8):623-32. PubMed ID: 7910947
[TBL] [Abstract][Full Text] [Related]
31. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
Liu J; Finke J; Krauss JC; Shu S; Plautz GE
Cancer Immunol Immunother; 1998 Jul; 46(5):268-76. PubMed ID: 9690455
[TBL] [Abstract][Full Text] [Related]
33. Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection.
Seitzer U; Kayser K; Höhn H; Entzian P; Wacker HH; Ploetz S; Flad HD; Gerdes J; Maeurer MJ
Immunology; 2001 Nov; 104(3):269-77. PubMed ID: 11722641
[TBL] [Abstract][Full Text] [Related]
34. MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta-chain, and induces apoptosis.
Skov S; Bregenholt S; Claesson MH
J Immunol; 1997 Apr; 158(7):3189-96. PubMed ID: 9120273
[TBL] [Abstract][Full Text] [Related]
35. Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules.
Guarini A; Riera L; Cignetti A; Montacchini L; Massaia M; Foa R
Blood; 1997 Jan; 89(1):212-8. PubMed ID: 8978294
[TBL] [Abstract][Full Text] [Related]
36. The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration.
Farace F; Angevin E; Vanderplancke J; Escudier B; Triebel F
Int J Cancer; 1994 Dec; 59(6):752-5. PubMed ID: 7989113
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
[TBL] [Abstract][Full Text] [Related]
38. Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion.
Tosello AC; Mary F; Amiot M; Bernard A; Mary D
J Inflamm; 1998; 48(1):13-27. PubMed ID: 9368189
[TBL] [Abstract][Full Text] [Related]
39. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
Fan K; Borden E; Yi T
J Interferon Cytokine Res; 2009 Aug; 29(8):451-60. PubMed ID: 19514839
[TBL] [Abstract][Full Text] [Related]
40. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
